{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:47:20Z","timestamp":1793771240337,"version":"4.6.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.beem.2024.101888","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T15:00:11Z","timestamp":1708614011000},"page":"101888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of acromegaly with oral octreotide"],"prefix":"10.1016","volume":"38","author":[{"given":"Ilan","family":"Remba-Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa B.","family":"Nachtigall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2024.101888_bib1","article-title":"National acromegaly registries","volume":"33","author":"Maione","year":"2019","journal-title":"Best Pr Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","article-title":"Epidemiology of acromegaly: review of population studies","volume":"20","author":"Lavrentaki","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101888_bib3","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11102-016-0725-2","article-title":"Challenges in the diagnosis and management of acromegaly: a focus on comorbidities","volume":"19","author":"Abreu","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101888_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrendo.2018.22","article-title":"Growth hormone - past, present and future","volume":"14","author":"Ranke","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101888_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI19933","article-title":"Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis","volume":"114","author":"Murray","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beem.2024.101888_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/ENDO:20:3:255","article-title":"Somatostatin and somatostatin receptor physiology","volume":"20","author":"Barnett","year":"2003","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101888_bib8","first-page":"1386","article-title":"Somatostatin receptor subtype gene expression in pituitary adenomas","volume":"80","author":"Miller","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0024-3205(94)00956-2","article-title":"Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors","volume":"56","author":"Panetta","year":"1995","journal-title":"Life Sci"},{"key":"10.1016\/j.beem.2024.101888_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101888_bib11","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1210\/jc.2004-1093","article-title":"Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly","volume":"90","author":"Bevan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib13","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1210\/clinem\/dgaa868","article-title":"Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis","volume":"106","author":"Broersen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","article-title":"Pituitary somatostatin receptor signaling","volume":"21","author":"Ben-Shlomo","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib16","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1210\/endo-113-5-1726","article-title":"Stimulation of adenosine 3\u2032,5\u2032-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro","volume":"113","author":"Bilezikjian","year":"1983","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2024.101888_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/jn.00872.2006","article-title":"Mechanism of spontaneous and receptor-controlled electrical activity in pituitary somatotrophs: experiments and theory","volume":"98","author":"Tsaneva-Atanasova","year":"2007","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.beem.2024.101888_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocr"},{"key":"10.1016\/j.beem.2024.101888_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mce.2007.08.012","article-title":"Somatostatin\/somatostatin receptor signalling: phosphotyrosine phosphatases","volume":"286","author":"Florio","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2024.101888_bib20","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib21","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1210\/jcem.87.7.8665","article-title":"Somatostatin analogs in acromegaly","volume":"87","author":"Freda","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","article-title":"Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension","volume":"13","author":"Melmed","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101888_bib23","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1210\/jc.2014-2900","article-title":"Surgical interventions and medical treatments in treatment-na\u00efve patients with acromegaly: systematic review and meta-analysis","volume":"99","author":"Abu Dabrh","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2024.101888_bib25","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101888_bib27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101888_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101888_bib29","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1210\/clinem\/dgz187","article-title":"Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time","volume":"105","author":"Ghajar","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.canlet.2015.01.037","article-title":"Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas","volume":"359","author":"Luque","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.beem.2024.101888_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","article-title":"Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101888_bib32","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib33","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","author":"Hofland","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib34","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2024.101888_bib36","first-page":"2768","article-title":"Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study","volume":"80","author":"Newman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0026-0495(92)90027-8","article-title":"Gallstones during octreotide therapy","volume":"41","author":"Dowling","year":"1992","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2024.101888_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101888_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2024.101888_bib40","doi-asserted-by":"crossref","first-page":"e3644","DOI":"10.1210\/clinem\/dgac385","article-title":"IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands","volume":"107","author":"Maione","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/medicina57121287","article-title":"Self-administration of long-acting somatostatin analogues in NET patients-does it affect the clinical outcome?","volume":"57","author":"Sowa-Staszczak","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.beem.2024.101888_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/IJGM.S38594","article-title":"Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment","volume":"6","author":"Adelman","year":"2013","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.beem.2024.101888_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands","volume":"12","author":"Fleseriu","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2024.101888_bib44","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1476-5381.1992.tb09057.x","article-title":"Enteral absorption of octreotide","volume":"105","author":"Flicker","year":"1992","journal-title":"Br J Pharm"},{"key":"10.1016\/j.beem.2024.101888_bib45","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib46","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/mp500809f","article-title":"Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs","volume":"12","author":"Wang","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.beem.2024.101888_bib47","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","article-title":"A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms","volume":"31","author":"Tuvia","year":"2014","journal-title":"Pharm Res"},{"key":"10.1016\/j.beem.2024.101888_bib48","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.ddtec.2011.11.006","article-title":"Overcoming poor permeability: translating permeation enhancers for oral peptide delivery","volume":"9","author":"Maher","year":"2012","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.beem.2024.101888_bib49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2133\/dmpk.22.67","article-title":"Mechanistic analysis for drug permeation through intestinal membrane","volume":"22","author":"Hayashi","year":"2007","journal-title":"Drug Metab Pharm"},{"key":"10.1016\/j.beem.2024.101888_bib50","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1084\/jem.20071416","article-title":"JAM-A regulates permeability and inflammation in the intestine in vivo","volume":"204","author":"Laukoetter","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.beem.2024.101888_bib51","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1053\/j.gastro.2008.10.081","article-title":"Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis","volume":"136","author":"Su","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beem.2024.101888_bib52","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib53","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib54","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1530\/EJE-22-0220","article-title":"Durable biochemical response and safety with oral octreotide capsules in acromegaly","volume":"187","author":"Samson","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101888_bib55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2024.101888_bib56","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1210\/clinem\/dgad365","article-title":"MPOWERED trial open-label extension: long-term efficacy and safety data for oral octreotide capsules in acromegaly","volume":"108","author":"Fleseriu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101888_bib58","unstructured":"Amryt Pharmaceuticals. Mycapssa (prescribing information) 2022. \u3008https:\/\/label.mycapssa.com\/wp-content\/uploads\/sites\/4\/2022\/03\/Mycapssa-PI-PG-IFU-Mar2022_v3-FINAL.pdf\u3009 (Accessed December 26, 2023)."},{"key":"10.1016\/j.beem.2024.101888_bib59","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib60","unstructured":"Texas Department of State Health Services. Wholesale Acquisition Cost (WAC) 2024. \u3008https:\/\/www.dshs.texas.gov\/prescription-drug-price-disclosure-program\/data-overview\u3009 (Accessed February 13, 2024)."},{"key":"10.1016\/j.beem.2024.101888_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12112669","article-title":"Approach of acromegaly during pregnancy","volume":"12","author":"Popescu","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.beem.2024.101888_bib62","first-page":"1042","article-title":"Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management","volume":"90","author":"Redfern","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.beem.2024.101888_bib63","doi-asserted-by":"crossref","first-page":"734","DOI":"10.21037\/atm-22-414","article-title":"Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study","volume":"10","author":"Zhao","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.beem.2024.101888_bib64","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2009-0941","article-title":"Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study","volume":"94","author":"Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101888_bib65","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2265.2006.02639.x","article-title":"Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients","volume":"65","author":"Fatti","year":"2006","journal-title":"Clin Endocrinol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T18:47:47Z","timestamp":1721328467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24000393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1521690X24000393"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101888","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of acromegaly with oral octreotide","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101888","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101888"}}